Akura Medical has filed a notice of an exempt offering of securities to raise $35,000,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Akura Medical is raising $35,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Murali Srivathsa played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Akura Medical
Focused on providing effective and easy-to-use clot removal to efficiently treat venous thromboembolisms (VTE). Akura Medical, Inc. is a portfolio company of Shifamed, LLC., a highly-specialized medical innovation hub focused on developing advanced solutions that get to market faster, reduce risk, increase impact, and forge a path toward a world where all people are able to lead longer, healthier lives.
To learn more about Akura Medical, visit http://www.akuramed.com/
Contact:
Murali Srivathsa, Chief Executive Officer
408-560-2500
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.